ArticleFrontiers in ophthalmology2026
Longitudinal changes in anatomic biomarkers on optical coherence tomography angiography in diabetic retinopathy.
Article in Frontiers in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
Purpose: To identify optical coherence tomography angiography (OCTA)-derived biomarkers correlating with diabetic retinopathy (DR) severity and characterize longitudinal retinal microvascular changes across DR stages. Methods: In this 3-year prospective study, we analyzed OCTA images from 328 eyes of 164 adults with type II diabetes and 33 eyes from 17 healthy controls. Patients were categorized as no DR, mild, moderate, or severe nonproliferative DR (NPDR), or proliferative DR (PDR) at baseline. Bilateral OCTA scans were obtained at each visit and processed with a validated pipeline to extract seven microvascular indices from the superficial and deep capillary plexuses: vessel density, skeleton density, acircularity index, average vessel caliber, foveal avascular zone (FAZ) area, FAZ perimeter, and fractal dimensions. Linear regression quantified changes over time, and intergroup comparisons were made using ANOVA and Results: A total of 361 eyes (328 diabetic eyes and 33 control eyes) were followed for a mean of 3 years. Longitudinal analysis demonstrated stage-dependent microvascular changes across DR severity groups. In the deep capillary plexus, eyes with severe NPDR exhibited greater annual declines in vessel density (-0.563 ± 0.39% per year) and skeleton density (-0.296 ± 0.23% per year) compared with controls. Acircularity index increased over time, with greater annual increases observed in severe NPDR relative to mild NPDR (0.16 ± 0.12% per year), consistent with progressive macular ischemia. In the superficial plexus, eyes with severe NPDR showed greater annual reductions in average vessel caliber (-4.5e-4 ± 0.0005% per year) compared with earlier disease stages. Across the cohort, most OCTA metrics demonstrated small but statistically significant longitudinal trends, reflecting gradual microvascular remodeling detectable over repeated measurements. Conclusions: Longitudinal OCTA analysis reveals stage-specific microvascular changes in DR. These dynamic biomarkers may provide early indicators of DR progression and offer a quantitative foundation for individualized monitoring and timely intervention strategies. Translational Relevance: OCTA-derived biomarkers offer a noninvasive tool for detecting early DR changes and guiding personalized care strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.